According to the company, it has installed development and analytical equipment to support the development of highly potent APIs (HPAPIs), including a new 2,800-liter hydrogenator and 1,500mm diameter centrifuge.
Equipment installation and validation with be concluded by the end of 2017.
The small molecule and generic Active Pharmaceutical Ingredients (APIs) manufacturer opened the pilot plant in October 2016 at which time it said further upgrades would follow in order to support the production of Class 3/4 high potency products.
The cGMP plant can produce batch sizes from 1kg to 15kg.
Cambrex also invested $24m in a new Charles City, Iowa plant earlier this year. The facility is expected to be open in 2019.
The company’s High Point, NC-based facility was also expanded to include a new $3.2m, 11,000 square foot analytical laboratory in August.